3063 Ridogrel Ridogrel is only found in individuals that have used or taken this drug. It is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. Thromboxane synthetase produces thromboxane in platelets. Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. Therefore by inhibiting the production and promotion of thromboxane, thrombolysis is enhanced. 110140-89-1 5362391 C18H17F3N2O3 366.119130 White powder. 8.39e-03 g/L Rapidly absorbed after oral administration (30-60 min) Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. Thromboxane synthetase produces thromboxane in platelets. Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. Therefore by inhibiting the production and promotion of thromboxane, thrombolysis is enhanced. No indication of carcinogenicity to humans (not listed by IARC). Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction. 2009-07-21T20:28:39Z 2026-05-14T16:58:45Z 127439 Ridogrel DB01207 true OC(=O)CCCCO\N=C(\C1=CN=CC=C1)C1=CC(=CC=C1)C(F)(F)F C18H17F3N2O3 InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+ GLLPUTYLZIKEGF-HAVVHWLPSA-N 366.3344 366.119127035 Exogenous Solid 4.3 HMDB15338 CHEMBL280728 4515025 CHEM002378 DTXSID90872935 NS00068597 5-{[(E)-[(pyridin-3-yl)[3-(trifluoromethyl)phenyl]methylidene]amino]oxy}pentanoic acid 71.78 88.8943 34.94102375669082 9 5 1 3.501608187006648 4.25638291462859 -1 2 3.24 -4.64 8.39e-03 g/l